Dendreon (DNDN) +6.9% - although down from earlier highs - on rumors it might be trying to sell...

Dendreon (DNDN) +6.9% - although down from earlier highs - on rumors it might be trying to sell itself, with Celgene (CELG -0.2%) one name being mooted. Feeding the speculation beast is new CEO John Johnson working from New Jersey even though the company is based in Seattle.
From other sites
Comments (6)
  • Gary Jakacky
    , contributor
    Comments (2882) | Send Message
    What a joke of a company. When ya can't sell your product, sell additional shares. When the saps gettired of bying additional shares, sell the whole firm!
    24 Jul 2012, 11:31 AM Reply Like
  • Mike Maher
    , contributor
    Comments (2849) | Send Message
    Trying to sell the firm after shares fall 80% from the 52-week high seems like a poor strategy.
    24 Jul 2012, 11:44 AM Reply Like
  • Adel.Nashville
    , contributor
    Comments (47) | Send Message
    This is "rumors "
    Read what JJ said, this is his last company, that does not sound logical
    24 Jul 2012, 11:54 AM Reply Like
  • barneyb1
    , contributor
    Comments (2) | Send Message
    My oncologist started advocating Provenge for me even before it got approved. Then when it was appoved, we referred me to a specialist that did the Provenge thing but he informed me at that time that it was not accepted by Medicare. Later when it was accepted by Medicare, I went for an interview and found out that it was only being used on patients whose prostate cancer had metastized. Fortunately mine has not and I was turned down.
    I bought stock in DnDn and made some good money it in non-approved and early approved days but I don't understand the management of this company and their inability to sell this product to the medical profession and to the public. Why wait until the patient is dead and give them the treatment? It appears to me that this company and Dr. Gold in particular has developed Provenge (their only product) for the sole reason to make Dr. Gold rich...and it has. Hasn't done ole barney b smith much good though.
    24 Jul 2012, 01:46 PM Reply Like
  • Adel.Nashville
    , contributor
    Comments (47) | Send Message
    You do not build a huge company over night
    If your oncologist started advocating Provenge for you even before it got approved, you should have more trust in it's potential now.
    24 Jul 2012, 02:59 PM Reply Like
  • rockiemoon
    , contributor
    Comments (27) | Send Message
    Provenge is a good drug, but the previous sale team really sucks
    24 Jul 2012, 05:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs